Non-COPD: 69.6% p= statistically significant” “not Statin COPD: 85.9% Non-COPD: 89.5% p<0.001 P2Y12 inhibitor COPD: 65.5% Non-COPD: 71.6% p<0.001 Rothnie 2015 All UK patients admitted to 300161 patients with a first MI STEMI hospital in the MINAP registry In-hospital management between 2003-2013 Primary PCI OR 0.87 (95% CI, 0.83-0.92)* Discharge medicines Aspirin OR 0.90 (95% CI, 0.85-0.94)* β-blocker OR 0.26 (95% CI, 0.25-0.27)* ACE inhibitor or angiotensin receptor blocker OR 0.89 (95% CI, 0.85-0.93)* Statin OR 0.91 (95% CI, 0.86-0.95)* P2Y12 inhibitor OR 0.98 (95% CI, 0.94-1.03)* In-hospital management
Non-COPD: 69.6% p= “not statistically significant” Statin COPD: 85.9% Non-COPD: 89.5% p<0.001 P2Y12 inhibitor COPD: 65.5% Non-COPD: 71.6% p<0.001 Rothnie 2015 All UK patients admitted to hospital in the MINAP registry between 2003-2013 300161 patients with a first MI STEMI In-hospital management Primary PCI OR 0.87 (95% CI, 0.83-0.92)* Discharge medicines Aspirin OR 0.90 (95% CI, 0.85-0.94)* β-blocker OR 0.26 (95% CI, 0.25-0.27)* ACE inhibitor or angiotensin receptor blocker OR 0.89 (95% CI, 0.85-0.93)* Statin OR 0.91 (95% CI, 0.86-0.95)* P2Y12 inhibitor OR 0.98 (95% CI, 0.94-1.03)* In-hospital management
ehj%20qcco%20paper%201.0.docx